[HTML][HTML] Gene expression changes associated with erlotinib response in glioma cell lines
A García-Claver, M Lorente, P Mur… - European Journal of …, 2013 - Elsevier
Erlotinib (ERL), a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor
(EGFR), is used as a second line treatment for glioma therapy, with controversial findings …
(EGFR), is used as a second line treatment for glioma therapy, with controversial findings …
Gene expression changes associated with erlotinib response in glioma cell lines.
A García-Claver, M Lorente, P Mur… - European Journal of …, 2013 - europepmc.org
Erlotinib (ERL), a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor
(EGFR), is used as a second line treatment for glioma therapy, with controversial findings …
(EGFR), is used as a second line treatment for glioma therapy, with controversial findings …
[引用][C] Gene expression changes associated with erlotinib response in glioma cell lines
A García-Claver, M Lorente, P Mur… - … Journal of Cancer, 2013 - produccioncientifica.ucm.es
Gene expression changes associated with erlotinib response in glioma cell lines
A García-Claver, M Lorente, P Mur… - European Journal of …, 2013 - infona.pl
Erlotinib (ERL), a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor
(EGFR), is used as a second line treatment for glioma therapy, with controversial findings …
(EGFR), is used as a second line treatment for glioma therapy, with controversial findings …
Gene expression changes associated with erlotinib response in glioma cell lines
A García-Claver, M Lorente, P Mur… - European Journal of …, 2013 - ejcancer.com
Erlotinib (ERL), a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor
(EGFR), is used as a second line treatment for glioma therapy, with controversial findings …
(EGFR), is used as a second line treatment for glioma therapy, with controversial findings …
Gene expression changes associated with erlotinib response in glioma cell lines
A García-Claver, M Lorente, P Mur… - … journal of cancer …, 2013 - pubmed.ncbi.nlm.nih.gov
Erlotinib (ERL), a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor
(EGFR), is used as a second line treatment for glioma therapy, with controversial findings …
(EGFR), is used as a second line treatment for glioma therapy, with controversial findings …
[引用][C] Gene expression changes associated with erlotinib response in glioma cell lines
A GARCIA-CLAVER, M LORENTE… - European journal of …, 2013 - pascal-francis.inist.fr
Gene expression changes associated with erlotinib response in glioma cell lines CNRS Inist
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search Advanced …
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search Advanced …